Could a simple supplement boost CAR-T therapy for lymphoma?

NCT ID NCT06610344

First seen Feb 23, 2026 · Last updated May 14, 2026 · Updated 10 times

Summary

This early study looks at whether a supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people with large B-cell lymphoma who are receiving standard CAR-T cell therapy. Five adults will take the supplement by mouth during their treatment. Researchers will also check for changes in gut bacteria and immune cells, but the main goal is to see if the supplement can be used without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Abramson Cancer Center at University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.